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(S. Qu).Very low density lipoprotein receptors (VLDLR) including type I and type II are known to affect cell
functions by binding to its extracellular ligands. However, the effect of these ligands on VLDLR
expression remains elusive. Tissue factor pathway inhibitor (TFPI) and urokinase plasminogen acti-
vator and plasminogen activator inhibitor 1 (uPA–PAI-1) complex, two ligands of VLDLR, were used
to examine their effects on VLDLR expression. TFPI treatment decreased type II VLDLR expression,
inhibited cell proliferation and migration, and degradated b-catenin in SGC7901 cells. However,
uPA–PAI-1 complex, increased type II VLDLR expression with promoted cell proliferation and migra-
tion and stabilization of b-catenin. These results indicated that extracellular ligands can change the
expression of type II VLDLR to affect cell proliferation and migration.
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The very low density lipoprotein receptor (VLDLR) is a member
of the low density lipoprotein receptor (LDLR) superfamily. Two
forms of VLDLR, with (type I) and without (type II) the O-linked su-
gar domain, are generated through alternative splicing [1]. Type I
VLDLR is mainly distributed in heart and skeletal muscles relating
to fatty acid metabolism, whereas type II VLDLR is predominant in
non-muscle tissue, including kidney, spleen, adrenal gland, lung,
etc [1–3]. There are also reports demonstrating that VLDLR iso-
forms are expressed in various cancer tissues [4,5], suggesting that
VLDLR is likely to be involved in the pathogenesis of cancers. A pre-
vious study has shown that transient overexpression of the type I
VLDLR in COS-7 cells strongly inhibited cell growth in a ligand-
independent manner, which has been demonstrated to be medi-
ated by the O-linked sugar domain of type I VLDLR [6]. Our recentchemical Societies. Published by E
, Department of Biomedical
ing, South China University of
7.
nd Molecular Biology, Tongji
echnology, No. 13 Hangkong
), qushen@mails.tjmu.edu.cnstudy has also shown that the stable transfection of SGC7901 cells
with type II VLDLR recombinant DNA induced cell proliferation and
migration, while type I VLDLR transfection decreased cell prolifer-
ation and migration [7]. Both the previous report and our recent
study have demonstrated a ligand-independent effect of VLDLR.
Besides the receptor mediated ligand-independent effects,
VLDLR can also exert various functions by binding to their ligands
[8]. By using VLDLR ligands, the tissue factor pathway inhibitor
(TFPI) [9,10] and the complex of urokinase-type plasminogen acti-
vator and plasminogen activator inhibitor 1 (uPA–PAI-1) [11,12], it
has been reported that uPA–PAI-1 complex can promote cell prolif-
eration and migration through VLDLR by activating extracellular
signal-regulates kinase (ERK) pathway [11,12] and TFPI can inhibit
cell proliferation through VLDLR by inducing JADD45B and p38 sig-
nal pathway [9,10]. These studies showed a ligand-dependent ef-
fect of VLDLR. Nevertheless, it is unclear whether these ligands
exert their roles through altering the expression levels of these
two subtypes of VLDLR.
In this study, the two VLDLR ligands (TFPI or uPA–PAI-1) and
the human gastric adenocarcinoma cell line SGC7901 were em-
ployed to investigate the effect of these ligands on VLDLR subtypes
expression and cell proliferation and migration. Our results
showed that TFPI treatment decreased the expression of type II
VLDLR without affecting type I VLDLR. However, uPA–PAI-1lsevier B.V. All rights reserved.
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expression. Cell proliferation and migration were further found
to be decreased by TFPI and increased by uPA–PAI-1 complex,
respectively. Furthermore, a decrease of ERK1/2 phosphorylation
and degradation of b-catenin was observed in SGC7901 cells upon
TFPI treatment. The treatment of uPA–PAI-1 complex, however, in-
creased the phosphorylation of ERK1/2 and stabilized b-catenin by
reducing its phosphorylation. These results suggested that extra-
cellular ligands can change the expression of type II VLDLR to affect
cell proliferation and migration.
2. Materials and methods
2.1. Reagents
The uPA was from Chemicon International (Temecula, CA, USA).
TFPI and PAI-1 were obtained from Calbiochem (San Diego, CA,
USA). The uPA–PAI-1 complex (10 nM) was pre-formed by mixing
uPA with PAI-1 at a 1:1 molar ratio at 37 C for 20 min. (3-(4,5-
Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) (MTT)
was purchased from Sigma (St. Louis, MO). IgG6A6 hybridoma cells
were from ATCC.
2.2. Preparation of monoclonal antibodies against the C-terminal of
VLDLR
IgG6A6 hybridoma cells, which were prepared as previously de-
scribed [13], were maintained in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM) supplemented with 10% fetal bovine serum (FBS),
100 U/ml penicillin, 100 lg/ml streptomycin and 2 mM L-gluta-
mine in a humidiﬁed atmosphere of 5% CO2 at 37 C. BALB/c female
mice were injected with 0.5 ml Freund’s incomplete adjuvant.
After a week, the mice were injected with 1  106 IgG6A6 cells sus-
pended in 0.5 ml phosphate-buffered saline (PBS). The ascites were
collected two weeks later and the antibodies were puriﬁed by pro-
tein A afﬁnity chromatography.
2.3. Cell culture
SGC7901 cells were maintained in RPMI 1640 medium supple-
mented with 10% FBS, 100 U/ml penicillin, 100 lg/ml streptomycin
and 2 mM L-glutamine in a humidiﬁed atmosphere of 5% CO2 at
37 C. The cells were incubated in serum-free medium for 12 h be-
fore the treatment with 1 lM TFPI or 10 nM uPA–PAI-1 complex
for indicated times.
2.4. Western blotting analysis
The cell pellet was lysed in buffer containing 10 mM Tris–HCl
(pH 8.0), 1 mM MgCl2, 1% NP-40, 0.5% sodium deoxycholate,
1 mM phenylmethysulfonyl ﬂuoride, 1 mg/L aprotinin and
0.02 mg/L leupeptin. Following cell protein quantitation, 60 lg of
protein per sample were subjected to 7.5% SDS–PAGE. The proteins
separated on the PAGE gel were transferred to a nitrocellulose
membrane, which was blocked for 2 h at room temperature. The
membrane was then incubated overnight at 4 C with monoclonal
antibodies against VLDLR, against b-actin (Santa Cruz Biotechnol-
ogy, CA, USA) or polyclonal rabbit anti-human phosphop44/42
MAP kinase (Cell Signaling Technology, Beverly, MA, USA) and rab-
bit polyclonal anti-rat ERK2 (C-14) (Santa Cruz Biotechnology) or
mouse monoclonal anti-human b-catenin and Rabbit anti-phos-
pho-b-catenin (S33/S37) (R&D Systems, Minneapolis, MN, USA),
followed by incubation with a secondary antibody conjugated with
horseradish peroxidase. Immunoreactive bands were visualized by
an enhanced chemiluminescence (ECL) system and the level of pro-tein expression determined using Image Quant TL software (Amer-
sham Pharmacia Biotech, Piscataway, NJ, USA).
2.5. Cell proliferation assays
The cells were seeded at a density of 5  103/well and cul-
tured in RPMI 1640 containing 10% FBS for 24 h and then in ser-
um-free RPMI 1640 for another 24 h. The cells were treated with
1 lM TFPI or 10 nM uPA–PAI-1 complex for 12, 24, 36 and 48 h
and then incubated for 4 h with 5 mg/ml MTT. Each treatment
was done with 10 wells in all assays. Dimethyl sulfoxide (DMSO)
was used to dissolve the formazan crystals. The absorbance was
measured with an ELISA-plate reader (Bio-Tek Instruments, Inc)
at 490 nm.
2.6. Cell migration assays
The cells were preincubated with 1 lM TFPI in serum-free RPMI
1640 for 12 h at 37 C or with 10 nM uPA–PAI-1 complex for
15 min and then transferred to the top chamber at a density of
106 cells/ml (100 ll). The bottom chamber contained RPMI 1640
supplemented with 10% FBS. The cells were allowed to migrate
for 6 h at 37 C. Non-migrating cells were removed from the top
surfaces with a cotton swab. The membranes were ﬁxed in 4%
paraform and stained with hematoxylin. The cells penetrated to
the bottom surface of each membrane were counted with random
10 ﬁelds on each microscope slide.
2.7. RT-PCR
Four micrograms of total RNA, isolated using Trizol solution,
were applied to PCR reaction and cDNA was synthesized by re-
verse-transcription under the conditions as follows. The primers
used were 50-GGA TGA CAT CAA GGG CAT TCA G-30 and 50-GTC
ACA GTC CGC CAA ATG AAC C-30 for MMP-2, 50-CAA GTG GGC
TAC GTG ACC TAT GAC-30 and 50-CCC TTT CCT CCA GAA CAG AAT
ACC-30 for MMP-9, and 50-TGA GAC CTT CAA CAC CCC AG-30 and
50-GCC ATC TCT TGC TCG AAG TC-30 for b-actin. The thermal cy-
cling conditions were 94 C for 4 min and 94 C, 30 s; 57 C, 45 s
and 72 C, 45 s, for 35 cycles. The ﬁnal cycle was extended at
72 C for 10 min. PCR products identiﬁed by 2% agarose gel electro-
phoresis were analyzed using Image Quant TL software.
2.8. Statistical analysis
Experiments were repeated a minimum of three times unless
otherwise noted. Data are expressed as the mean ± S.D. The signif-
icance was determined by one-way ANOVA for comparisons
amongmultiple groups and student t test for comparisons between
two groups with SPSS12.0. The statistical signiﬁcance of P < 0.05 or
0.01 or 0.001 was indicated in the ﬁgure legends.
3. Results
3.1. Cell proliferation and migration
When treated with TFPI for 36 h, the cell proliferation was grad-
ually decreased to 51 ± 6% of that of the control values (Fig. 1A).
The cell migration was inhibited to 58 ± 7% of that of the control
cells after 12 h of TFPI treatment (Fig. 1B). In comparison, the cell
growth was increased to 173 ± 7% of that of the control after 36 h
with uPA–PAI-1 complex incubation (Fig. 1A). The migration for
the cells preincubated with uPA–PAI-1 complex for 15 min was in-
creased to 301 ± 26% of that of the non-stimulating cells after 6 h
(Fig. 1B).
Fig. 1. Cell proliferation and migration assays. After the cells were treated as
described in the method, the cells were incubated with 1 lM TFPI or 10 nM uPA–
PAI-1 complex for 12, 24, 36, 48 h and then incubated for 4 h with 5 mg/ml MTT for
proliferation assay (A). The cells were preincubated with 1 lM TFPI for 12 h or with
10 nM uPA–PAI-1 complexes for 15 min at 37 C prior to the migration assay (B), as
described in the method. Data are expressed as mean ± S.D. of three experiments.
*P < 0.05, **P < 0.01, or ***P < 0.001, compared to the control.
Fig. 2. Expression of two VLDLR subtypes in the cells incubated with TFPI or uPA–
PAI-1 complex. Western blotting images of type I VLDLR, type II VLDLR and b-actin
expression by the SGC7901 cells incubated with 1 lM TFPI (A) or 10 nM uPA–PAI-1
complex (D). The data from Western blotting (A) were analyzed using b-actin as
internal standard and depicted in (B). The ratio of type II VLDLR to type I VLDLR in
TFPI treated cells was calculated (C). The data from Western blotting (D) were
analyzed and shown in Fig. 3E. The ratio of type II VLDLR to type I VLDLR in uPA–
PAI-1 treated cells was shown in Fig. 3F. Data are expressed as mean ± S.D. of three
experiments. *P < 0.05, **P < 0.01, or ***P < 0.001, compared with the control.
Fig. 3. Phosphorylation of ERK1/2 in SGC7901 cells treated with uPA–PAI-1
complex or TFPI. Western blotting analysis detecting the phosphorylated ERK1/2
in SGC7901 cells treated with 10 nM uPA–PAI-1 complex (A) or 1 lM TFPI (C) for
the indicated times. The identical blot was probed with a polyclonal antibody
against total ERK1/2. Levels of phosphorylated ERK1/2 in cells treated with uPA–
PAI-1 complex (B) or TFPI (D) were internally standardized by comparison with the
corresponding level of total ERK1/2. Data are expressed as mean ± S.D. of three
experiments. * represents P < 0.05,**P < 0.01, or ***P < 0.001, compared to the
control.
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SGC7901 cells incubated with TFPI (Fig. 2A) for 48 h had a
reduction of 94 ± 7% in the expression of type II VLDLR compared
to non-TFPI-treated control cells (Fig. 2B), whereas the expressionof type I VLDLR was not changed and the ratio of type II VLDLR to
type I VLDLR was reduced by 92 ± 14% (Fig. 2C). On the other hand,
the level of type II VLDLR was signiﬁcantly increased when cells
were treated with uPA–PAI-1 complex (Fig. 2D). The expression
of type II VLDLR reached 1.76 ± 0.1 fold of that of the control cells
after 24 h. However, the expression of type I VLDLR was decreased
to 55 ± 3% of that of the control cells (Fig. 2E) and the ratio of type II
VLDLR to type I VLDLR was increased to 2.95 ± 0.08 fold of that of
the control cells after 24 h of uPA–PAI-1 complex treatment
(Fig. 2F).
3.3. Change of ERK1/2 activity
As the downstream of VLDLR, ERK signaling pathway was also
examined in this study. Preformed uPA–PAI-1 complex or TFPI
was immediately added to SGC7901 cell cultures, and ERK1/2
phosphorylation was monitored as a function of time. Similar to
the previous study [11,12], uPA–PAI-1 complex can quickly acti-
vate ERK1/2 after 5 min of incubation, and it sustained at least
30 min (Fig. 3A and B). In contrast to the uPA–PAI-1 complex, TFPI
decreased ERK phosphorylation gradually in SGC7901 cells (Fig. 3C
and D).
3.4. Change of b-catenin expression
After the incubation with TFPI for 48 h, the expression of b-cate-
nin was signiﬁcantly decreased and the expression of phosphory-
lated b-catenin was increased to 2.38 ± 0.03 fold of that of the
control cells (Fig. 4A and B). The expression of b-catenin was in-
creased by 92 ± 6.32% after 24 h uPA–PAI-1 complex treatment
and the expression of phosphorylated b-catenin was decreased sig-
niﬁcantly after 12 h and even could not be detected after 24 h
(Fig. 4C and D).
Fig. 4. Expression of b-catenin and phosphorylated b-catenin and MMP-2/9 mRNA
expression in SGC7901 cells treated with uPA–PAI-1 complex or TFPI. Western
blotting analysis detecting the b-catenin and phosphorylated b-catenin in SGC7901
cells treated with 10 nM uPA–PAI-1 complex (A) or 1 lM TFPI (C) for 12, 24, 48 h.
The identical blot was probed with a polyclonal antibody against b-actin. Levels of
b-catenin and phosphorylated b-catenin in uPA–PAI-1 complex (B) treated or TFPI
(D) treated cells were internally standardized by comparison with the correspond-
ing level of b-actin. SGC7901 cells were incubated with 10 nM uPA–PAI-1 complex
for 6 h (E) or 1 lM TFPI for 12 h (F). The mRNA expression of MMP-2/9 was tested
by RT-PCR, which was normalized with internal standard b-actin (G and H). Data
are expressed as mean ± S.D. of three experiments. * represents P < 0.05, **P < 0.01,
or ***P < 0.001, compared to the control.
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MMP activity can be controlled at transcription level [14], so we
examined the mRNA expression of MMP-2/9. In our study, MMP-2/
9 expression was increased to 2.24 ± 0.05 and 1.5 ± 0.10 fold of that
of the control cells respectively after 6 h uPA–PAI-1 treatment
(Fig. 4E and G). While after the incubation with TFPI for 12 h,
MMP-2/9 expression was decreased to 40 ± 8% and 43 ± 7%, respec-
tively (Fig. 4F and H).
4. Discussion
The coexisted ligand-dependent and ligand-independent func-
tions have been described before. For example, a splice variant of
growth hormone-releasing hormone receptor (GHRHR) stimu-
lated the proliferation of 3T3 ﬁbroblasts in the presence or ab-
sence of exogenous growth hormone-releasing hormone
(GHRH) [15]. Increasing evidence showed that VLDLR can also
mediate various functions both in ligand-independent and in li-
gand-dependent manners. Two kinds of VLDLR ligands TFPI and
uPA–PAI-1 complex have been found to affect cell proliferation
and migration via acting on VLDLR [9–12]. However, the effect
of these extracellular ligands on the expression pattern of twoVLDLR subtypes remains elusive. Similar to previous studies
[9,11–12], we showed that cell proliferation and migration were
inhibited by TFPI, but promoted by uPA–PAI-1 complex in this
study. In addition, we further demonstrated that TFPI treatment
decreased, while uPA–PAI-1 complex increased the expression of
type II VLDLR. These results suggested that the expression vari-
ation of type II VLDLR was consistent with the ligands-induced
changes of cell proliferation and migration.
It was reported that uPA–PAI-1 complex can promote cell pro-
liferation and migration through VLDLR by activating ERK pathway
[11,12] and TFPI can inhibit cell proliferation through VLDLR by
inducing JADD45B and p38 signaling pathway [9,10]. In this study,
ERK phosphorylation as the downstream signaling of VLDLR activ-
ity was also examined. The result of our present study is similar to
that of the previous study that uPA–PAI-1 complex could quickly
activate ERK1/2. In contrast to uPA–PAI-1 complex, we further
demonstrated that TFPI inhibited ERK phosphorylation in this
study, which may result from the activation of p38MAPK, as
stress-activated p38MAPK has been found to regulate LDL receptor
expression via negative modulation of p42/44 MAPK cascade [16].
It has been reported that transcription factors CCAAT/enhancer-
binding protein b (CEBP/b) and nuclear factor-Y (NF-Y), which
could be phosphorylated by ERK, could bind to discrete regulatory
elements in the very low density lipoprotein receptor promoter
[17,18]. So ERK pathway may also participate in the VLDLR expres-
sion variation caused by two extracellular VLDLR ligands, which
needs further study.
ERK activation has also been found to inactivate GSK-3b result-
ing in upregulation of b-catenin [19]. Wnt/b-catenin signaling
pathway has been demonstrated to play critical roles in cell prolif-
eration, migration, and tumorigenesis [20,21]. Our previous study
also showed that type II VLDLR increased the stability of b-catenin
and activated its target gene expression to promote cell prolifera-
tion and migration [7]. In this study, we analyzed the expression
of b-catenin in SGC7901 cell treated with these two ligands. Con-
sistent with previous studies, decrease of type II VLDLR expression
induced by TFPI resulted in increased phosphorylation of b-catenin
and degradation of b-catenin. The treatment of uPA–PAI-1, how-
ever, increased the expression of type II VLDLR leading to the accu-
mulation of b-catenin associated with decreased phosphorylation
of b-catenin. Furthermore, as the downstream target of b-catenin,
MMP-2/9 mRNA expression levels were also increased by uPA–
PAI-1 treatment but decreased by TFPI incubation. These results
also suggested that TFPI inhibited cell proliferation through the
down-regulation of type II VLDLR and the following degradation
of b-catenin, while uPA–PAI-1 promotes cell proliferation and
migration through up-regulation of type II VLDLR and subsequent
accumulation of b-catenin.
The high intrinsic proliferative activity is a feature of only the
truncated receptor and this activity can increase further after li-
gand binding [15]. Compared to the control, the cell proliferation
and migration of cells stably transfected with type II VLDLR were
increased to about 1.6 and 1.5 fold, respectively [7]. While in
cells treated with uPA–PAI-1 complex, the cell growth was in-
creased to 1.7 fold and the migration was increased to threefold
of that in the controls. This suggested that extracellular ligand
synergetically increased the function of VLDLR. It appears that
type II VLDLR deletion of O-linked sugar domain does not greatly
affect ligand binding properties of the receptor and its ability to
elicit mitogenic signals in the presence of extracellular ligand,
but introduces conformational changes that result in a form of
the receptor that is partially activated even in the absence of
the bound ligand. Therefore in the absence of extracellular li-
gand, type II VLDLR has some activity, which, however, can in-
crease further after ligand binding. This hypothesis has to be
validated by further studies.
Y. Di et al. / FEBS Letters 584 (2010) 3469–3473 3473In conclusion, our data suggested that TFPI or uPA–PAI-1 com-
plex can affect cell function in a ligand-dependent manner by
altering the expression of type II VLDLR.
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